Related Experiment Videos
Primary spinal intramedullary malignant melanoma: case report.
T Yamasaki1, H Kikuchi, J Yamashita
1Department of Neurosurgery, Kyoto University Medical School, Japan.
Neurosurgery
|July 1, 1989
Summary
This study presents a rare case of spinal melanoma treated with surgery, radiation, and chemotherapy. Intrathecal dacarbazine chemotherapy effectively reduced melanoma cells in the cerebrospinal fluid.
Area of Science:
- Neuro-oncology
- Medical imaging
- Pharmacology
Background:
- Primary spinal intramedullary malignant melanoma is exceptionally rare.
- This case involves a 31-year-old male with a T6 level tumor.
Observation:
- The patient underwent partial tumor removal, neuroaxis irradiation, and systemic interferon beta therapy.
- Melanoma cells were detected in cerebrospinal fluid (CSF) post-initial treatment.
- Intrathecal dacarbazine (DTIC) chemotherapy was administered to prevent CSF dissemination.
Findings:
- Cytological examination of CSF showed a significant reduction in melanoma cells after DTIC therapy.
- Pharmacokinetic studies revealed a biphasic elimination of DTIC from CSF with half-lives of 30 minutes and 5 hours.
- One-year follow-up MRI showed no significant residual tumor growth, recurrence, or metastasis.
Implications:
- This case highlights the potential efficacy of intrathecal DTIC chemotherapy for spinal melanoma.
- Magnetic Resonance Imaging (MRI) is valuable for monitoring treatment response and disease progression.
- Further research into multimodal treatment strategies for rare spinal cord tumors is warranted.